Based on the latest shareholder registry finalized in late March 2026, Hau Giang Pharmaceutical JSC (DHG) has reported a failure to meet the ownership distribution requirements necessary to maintain its public company status.
Key highlights regarding the company’s status:
-
Concentrated Ownership: Currently, the two largest shareholders hold over 94% of the charter capital. Specifically, a foreign strategic partner owns 51.01%, while a state capital management organization holds 43.31%. Since minority shareholders account for less than 6% of voting shares, the company falls short of the minimum 10% free-float requirement stipulated by current securities regulations.
-
2026 Financial Targets: The company has set a net revenue goal of 5,530 billion VND and a pre-tax profit target exceeding 1,000 billion VND. Expected growth rates range from 2% to 5% compared to the previous year’s performance.
-
Dividend Policy: The Board of Directors plans to maintain a 100% cash dividend for the 2025 fiscal year. The total payout is estimated at over 1,300 billion VND, scheduled to be distributed in two phases during mid and late 2026.
-
Business Performance: 2025 marked a significant milestone as sales revenue surpassed 6,000 billion VND for the first time. Despite pressures from operating costs and tax adjustments, after-tax profit maintained positive growth compared to the same period last year.
The Annual General Meeting of Shareholders is scheduled for April 21 in Can Tho to discuss the roadmap for adjusting the ownership structure and to approve the new business objectives.